CHAPTER 5 //

DEPLETION OF SAM50 SPECIFIC-ALLY TARGETS BCR-ABL-EXPRESSING LEUKEMIC STEM AND PROGENITOR CELLS BY INTERFERING WITH MITOCHONDRIAL FUNCTIONS

Marta E. Capala[1],
Edo Vellenga[1],
and Jan Jacob Schuringa[1]*.

[1]Department of Experimental Hematology, Cancer Research Center Groningen (CRCG), University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700RB Groningen, the Netherlands.

ABSTRACT

A high proliferation rate of malignant cells requires an increased energy production, both by anaerobic glucose metabolism and mitochondrial respiration. Moreover, increased levels of mitochondria-produced reactive oxygen species (ROS) promote survival of transformed cells and contribute to the disease progression both in solid tumors and leukemia. Consequently, interfering with mitochondrial metabolism has been used as a strategy to specifically target leukemic cells. SAM50 is a mitochondrial outer membrane protein involved in the formation of mitochondrial intermembrane space bridging complex (MIB). Although the importance of SAM50 in maintaining MIB integrity and in the assembly of mitochondrial respiratory chain complexes (MRC) has been described, its specific role in the normal and leukemic hematopoietic cells remains unknown. We observed that human leukemic cells display a specific dependence on SAM50 expression, as downregulation of SAM50 in BCR-ABL-expressing, but not normal human hematopoietic stem and progenitor cells (HSPCs) caused a dramatic decrease in growth, colony formation and replating capacity. Mitochondrial functions of BCR-ABL-expressing HSPCs were compromised, as seen by a decreased mitochondrial membrane potential and respiration. This effect of SAM50 downregulation was recapitulated in normal HSPCs exposed to cytokine-rich culture conditions that strongly enhanced proliferation. Both oncogene-transduced and cytokine-stimulated HSPCs showed increased mitochondrial membrane potential and increased ROS levels compared to their normal counterparts. Therefore, we postulate that human leukemic HSPCs are highly dependent on the proper functioning of mitochondria and that disruption of mitochondrial integrity may aid in targeting leukemic cells.

INTRODUCTION

Metabolic alterations are one of the hallmarks of carcinogenesis. An increased division rate of malignant cells results in elevated energy requirements, and consequently a more active metabolism. The phenomenon known as the Warburg effect describes the propensity of cancer cells to produce lactic acid from glucose even in aerobic conditions [1]. In fact, malignant cells utilize the anaerobic pathway of glucose metabolism next to mitochondrial respiration, which results in an increased glucose consumption rate and increased ATP production [2,3]. As a byproduct of their increased metabolism tumor cells generate high levels of reactive oxygen species (ROS), with mitochondria being one of the main sources [4–7]. Although elevated ROS levels are detrimental for healthy cells, in tumor cells they induce a variety of signaling pathways and activate transcription factors that promote growth, survival and malignant behavior [8–17]. Moreover, cancer cells counteract the overproduction of ROS by upregulating the antioxidant systems to prevent ROS-induced macromolecule damage, senescence and apoptosis induction [18–21].

The important role of mitochondrial metabolism for energy production and redox homeostasis has also been described in hematological malignancies. In acute myeloid leukemia (AML), inhibition of mitochondrial translation disrupted expression of mitochondrial respiratory complex (MRC) proteins and decreased respiration, specifically targeting leukemic cells [22]. In CML, deregulated expression of MRC components has been observed in leukemic stem cells (LSCs), indicating an increased level of oxidative phosphorylation that could reflect their high proliferation rate [23]. Elevated ROS levels have also been described in several leukemia models. Leukemic cells expressing internal tandem duplication of FLT3 (FLT3-ITD), the JAK2(V617F) activating mutation or the BCR-ABL kinase have shown increased levels of ROS causing DNA double strand breaks (DSB) to occur. This in turn has resulted in genomic instability leading to leukemia progression and development of therapy-resistant clones [24–27]. Moreover, elevated ROS levels increased survival of BCR-ABL-expressing cells through the activation of the PI3K/Akt signaling pathway [28]. Recently, RAC2 has been identified as a new key player in maintaining mitochondrial function in leukemic cells. In BCR-ABL-expressing cells, RAC2 has been shown to alter mitochondrial membrane potential and electron flow through the MRC complex III, generating high levels of ROS and causing DNA damage [29]. Downregulation of RAC2 in human BCR-ABL-transformed cord blood (CB) cells and primary blast crisis CML (BC CML) cells resulted in decreased mitochondrial membrane potential and decreased ROS production. Consequently, RAC2-deficient primitive leukemic cells showed increased apoptosis and diminished proliferation and self-renewal (Capala et al, submitted). We have identified that RAC2 may be required for the proper functioning of mitochondria due to its direct interaction with mitochondrial transport proteins, such as SAM50 and Metaxin 1 (Capala et al, submitted). These proteins, together with Metaxin 2, constitute the sorting and assembly machinery (SAM) in the mitochondrial outer membrane [30–32]. The SAM complex, by interacting with the mitochondrial inner membrane proteins mitofilin and CHCHD3

forms the mitochondrial intermembrane space bridging (MIB) complex involved in the assembly of MRC complexes. Consequently, downregulation of SAM50 was shown to destabilize the MIB complex, causing defective assembly of respiratory complexes and structurally abnormal cristae [33]. The specific role of SAM50 in normal and leukemic hematopoietic cells, however, remains unknown.

Here we report that human leukemic cells are specifically dependent on SAM50 expression. Downregulation of SAM50 in BCR-ABL-expressing, but not normal human hematopoietic stem and progenitor cells (HSPCs) cause a dramatic decrease in growth, colony formation and replating capacity, as well as a decreased mitochondrial membrane potential and respiration. This effect of SAM50 downregulation can be recapitulated in normal HSPCs when exposed to cytokine-rich culture conditions that strongly enhance proliferation. Both oncogene-transduced and cytokine-stimulated HSPCs show increased mitochondrial membrane potential and increased ROS levels compared to their normal counterparts. Therefore, we postulate that human leukemic HSPCs are highly dependent on the proper functioning of mitochondria and that disruption of mitochondrial integrity may aid in targeting leukemic cells.

MATERIALS AND METHODS

PRIMARY CELL ISOLATION AND CULTURE CONDITIONS

Neonatal cord blood (CB) was obtained from healthy full-term pregnancies after informed consent in accordance with the Declaration of Helsinki from the obstetrics departments of the University Medical Centre Groningen (UMCG) and Martini Hospital Groningen, Groningen, The Netherlands. All protocols were approved by the Medical Ethical Committee of the UMCG. After separation of mononuclear cells with lymphocyte separation medium (PAA Laboratories, Coble, Germany), CD34+ cells were isolated using a magnetically activated cell sorting (MACS) CD34 progenitor kit (Miltenyi Biotech, Amsterdam, The Netherlands). For the MS5 co-culture experiments, cells were grown in Gartner's medium consisting of α-modified essential medium (α−MEM; Fisher Scientific Europe, Emergo, The Netherlands) supplemented with 12.5% heat-inactivated fetal calf serum (Lonza, Leusden, The Netherlands), 12.5% heat-inactivated horse serum (Invitrogen, Breda, The Netherlands), 1% penicillin and streptomycin, 2 mM glutamine (all from PAA Laboratories), 57.2 µM β-mercaptoethanol (Merck Sharp & Dohme BV, Haarlem, The Netherlands) and 1 µM hydrocortisone (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands). Alternatively, co-cultures were expanded in Gartner's medium supplemented with 20 ng/mL interleukin 3 (IL-3; Gist-Brocades, Delft, The Netherlands) and stem cell factor (SCF; Amgen, Thousand Oaks, USA).

CELL LINES AND CULTURE CONDITIONS

293T embryonic kidney cells (ACC-635 DSMZ, Braunschweig, Germany) and PG13 packaging cells (ATCC CRL-10686, Wesel, Germany) were grown in DMEM medium with 200 mM glutamine (BioWhittaker, Veries, Belgium) supplemented with 10% FSC and 1% penicillin and streptomycin. K562 myelogenous leukemia cells (ACC-10,

DSMZ) were grown in RPMI medium with 200 mM glutamine (BioWhittaker) supplemented with 10% FCS, and 1% penicillin and streptomycin. MS5 murine stromal cells (ACC-441, DSMZ) were grown in αMEM with 200 mM glutamine (BioWhittaker) supplemented with 10% FCS and 1% penicillin and streptomycin.

RETRO- AND LENTIVIRUS GENERATION AND TRANSDUCTION

Stable PG13 producer cell lines of BCR-ABL retroviral constructs were generated and used as published previously [34]. Supernatants from the PG13 cells were harvested after 8 to 12 hours of incubation in human progenitor growth medium (HPGM; Cambrex, Verviers, Belgium) before the retroviral transduction rounds and passed through 0.45-µm filters (Sigma-Aldrich). Before the first transduction round, CD34+ CB cells were pre-stimulated for 48 hours in HPGM supplemented with 100 ng/mL SCF, FLT3 Ligand (Flt3L; both from Amgen) and thrombopoietin (TPO; Kirin, Tokyo, Japan). Three rounds of transduction were performed on retronectin-coated 24-well plates in the presence of the same cytokines as for pre-stimulation and 4 µg/mL polybrene (Sigma-Aldrich). During the last round of retroviral transduction with BCR-ABL, lentiviral shRNA particles were also added as described below. Short hairpin RNA (shRNA) sequences targeting SAM50 were ligated into pHR'trip vector using AcsI and SbfI restriction sites as previously described (ref. Capala et al. in press). For the control, scrambled (SCR) shRNA sequence was used. 293T embryonic kidney cells were transfected using FuGENE6 (Roche, Almere, The Netherlands) with 3 µg pCMV Δ8.91, 0.7 µg VSV-G, and 3 µg of pHR'trip vector constructs (shSCR or shSAM50). After 24 hours medium was changed to HPGM and after 12 hours supernatant containing lentiviral particles was harvested and either stored at -80°C or used fresh for transduction of target cells. CD34+ CB cells were subjected to three rounds of transduction with lentiviral particles, and BCR-ABL-transduced CD34+ CB cells were subjected to 1 round of transduction with lentiviral particles, together with the last round of retroviral transduction, in the presence of prestimulation cytokines and 4 µg/mL polybrene (Sigma) on retronectin-coated 24-well plates (Takara, Tokyo, Japan). K562 cells were subjected to one round of transduction with lentiviral particles in presence of 4 µg/mL polybrene, on retronectin-coated 24-well plate. After transduction, transduced green fluorescent protein (GFP)-positive, truncated nerve growth factor receptor (NGFR)-positive or double-positive cells were sorted on a MoFlo sorter (Dako Cytomation, Carpinteria, CA, USA).

LONG-TERM CULTURES ON STROMA, CFC AND LTC-IC ASSAY

After sorting, 5×10^4 CB cells or 5×10^3 BCR-ABL cells were plated onto T25 flask pre-coated with MS5 stromal cells in 5 mL of Gartner's medium in duplicate. Co-cultures were kept at 37°C and 5% CO_2 and cells were demi-depopulated weekly for analysis. Images of cobblestones were acquired on Leica DMIL inverted phase microscope (Leica Microsystems, Eindhoven,

Netherlands). CFC assays were performed as previously described [35]. For the LTC-IC assay, CB cells ere plated in the range of 6 to 1458 cells per well in a 96-well plate using Gartner's medium. Methylcellulose (StemCell Technologies, Grenoble, France) supplemented with 20 ng/mL of IL-3, 20 ng/mL of interleukin-6 (IL-6; Gist-Brocades), 20 ng/mL of G-CSF, 20 ng/mL of c-kit ligand (Amgen), and 6 U/mL of erythropoietin (Epo; Cilag, Eprex, Brussels, Belgium) was added at week 5. Two weeks later, wells containing CFCs were scored as positive and the LTC-IC frequency was calculated using L-Calc software (StemCell Technologies). May-Grünwald Giemsa staining was used to stain cytospins. Cytospin preparations were evaluated and photographed using a Leica DM3000 microscope equipped with a Leica DFC420C digital camera at a total magnification of x400.

FLOW CYTOMETRY ANALYSIS AND SORTING

All fluorescence-activated cell sorter (FACS) analyses were performed on a FACScalibur (Becton-Dickinson [BD], Alpen a/d Rijn, the Netherlands) and data were analyzed using WinList 3D (Verity Software House, Topsham, USA). Cells were sorted on a MoFlo sorter. Antibodies: NGFR-APC, CD14-PE and CD15-APC were obtained from BD.

MEASUREMENT OF MITOCHONDRIAL FUNCTIONS

Mitochondrial membrane potential was measured by flow cytometry using hexamethylindodicarbocyanine iodide (DilC1; Life Technologies, Bleiswijk, The Netherlands) as described previously [36]. Briefly, 5×10^5 cells were incubated with 50 ng/mL DilC1 for 30 min at $37°C$, washed twice in PBS, and DilC1 fluorescence was analyzed by FACS. To measure intracellular ROS levels, staining with CellROX Deep Red reagent was performed according to manufacturer's protocols (Life Technologies). Fluorescence of the probe was analyzed by FACS. OCR and ECAR were measured on XF^{e}24 Extracellular Flux Analyzer according to manufacturer's instructions (Seahorse Bioscience, Billerica, MA, USA). Briefly, XF^{e}24 Cell Culture Microplate was coated with poly-L-lysine (Sigma-Aldrich) and 2.5×10^5 K562 or BCR-ABL CB cells were plated per well in 100 μL XF Assay Medium (Seahorse Bioscience) supplemented with 4.5 g/L glucose 1 mM sodium pyruvate. Cells were allowed to attach for 30 min and XF Assay Medium was added to the final volume of 700 μL per well. XF^{e}24 Cell Culture Microplate was then loaded into XF^{e}24 Extracellular Flux Analyzer. OCR and ECAR values were derived as a mean of 5 consecutive measurements.

IMMUNOBLOTTING

Western blot analysis was performed according to standard protocols. Antibody against SAM50 and was kindly provided by Dr. V. Kozjak-Pavlovic (University of Würzburg, Würzburg, Germany). Secondary antibody (goat-anti-rabbit-HRP) was purchased from Dako Cytomation and used in 1:3000 dilutions. Binding of antibodies was detected by chemiluminescence, according to the manufacturer's instructions (Roche Diagnostics).

Figure 1. Human BCR-ABL-transduced HSPCs depend on SAM50 expression for their long-term expansion. (A) Cord blood (CB) CD34[+] stem/progenitor cells were co-transduced with a retroviral construct for BCR-ABL and either a control scrambled shRNA vector (shSCR) or with SAM50-targeting shRNA vectors (shSAM50). Transduced cells were sorted and used for Western blot analysis to determine SAM50 protein levels. Quantification of protein expression relative to control is indicated above each lane. (B) CB CD34[+] stem/progenitor cells were co-transduced with BCR-ABL and either control shSCR or with shSAM50. 5×10^3 double-transduced cells were sorted per group and plated on MS5 stromal cells. Cultures were demi-depopulated on indicated days for analysis and replated as indicated. The cumulative cell growth is shown for a representative experiment out of 4 independent experiments. (C) Fold reduction of cumulative cell growth of BCR-ABL and shRAC2-transduced CD34[+] CB cells in long-term co-culture as described in panel B, normalized to control cells. Cumulative expansion curves of 4 independent experiments are shown. (D) An example of day 14 cobblestones formed within the co-culture by shSCR- and shSAM50-transduced BCR-ABL cells. (E) Suspension cells from MS5 co-cultures as described in panel B were analyzed for progenitor frequency by CFC assay. 10^4 cells from each co-culture were plated in a CFC assay in methylcellulose in duplicate, and colonies were evaluated 2 weeks after plating. CFC cells were then harvested and 10^5 cells were re-plated to form secondary CFCs. Total CFC numbers are shown from a representative of 3 independent experiments. Error bars indicate standard deviation. (F) MGG-stained cytospins from week-1 suspension cells from co-cultures as described in panel B. CFU -GM, colony-forming unit-granulocyte-macrophage; BFU-E, burst forming unit-erythroid. * $P<0.05$.

STATISTICAL ANALYSIS

All values are expressed as means ± standard deviation (SD). Student's t test was used for all comparisons. Differences were considered statistically significant at $p<0.05$.

RESULTS

SAM50 EXPRESSION IS REQUIRED FOR THE LONG-TERM EXPANSION OF HUMAN BCR-ABL-EXPRESSING HSPCs

We have recently identified that the mitochondrial protein SAM50 is a *bona fide* interaction partner of RAC2 (Capala et al, submitted). To investigate in more detail the effect of SAM50 downregulation in human leukemic cells, we retrovirally transduced CD34+ CB cells to overexpress the BCR-ABL oncogene. Simultaneously, lentiviral transduction with a shRNA-containing construct was performed to downregulate SAM50, and double-transduced cells were sorted and plated in stromal co-cultures. The efficiency of SAM50 knockdown was assessed by Western blot (Fig. 1A). Strikingly, SAM50-depleted cells reproducibly showed a profound growth impairment within the first weeks of co-culture and a largely reduced replating capacity (Fig. 1B, C). Moreover, cobblestone formation by the shSAM50-transduced cells was impaired, indicating that the most primitive cell fraction was affected by SAM50 downregulation (Fig. 1D). Although progenitor frequencies assessed by CFC assay directly after sorting and at week 1 of co-culture were not significantly lower in SAM50-depleted co-cultures, at week 2 they were markedly reduced.

Importantly, also the replating potential of colony-forming cells was significantly decreased upon SAM50 downregulation (Fig. 1E). Differentiation of SAM50-depleted cells did not differ from the controls (Fig. 1F). Also cell viability, assessed by microscopical evaluation of the co-cultures and flow cytometry, was not affected by SAM50 downregulation (data not shown). Overall, these data suggested that BCR-ABL-transformed cells relied heavily on SAM50 expression for their long-term proliferation and self-renewal.

DEPLETION OF SAM50 RESULTS IN MITOCHONDRIAL DYSFUNCTION IN BCR-ABL-EXPRESSING HSPCs

Downregulation of SAM50 has been shown to destabilize the MIB complex, causing defective assembly of respiratory complexes [33]. To further investigate whether in a human leukemia model SAM50 depletion would result in mitochondrial impairment, we assessed the mitochondrial membrane potential in BCR-ABL-transduced CD34+ CB cells upon knockdown of SAM50. FACS analysis using the DilC mitochondrial dye revealed that depletion of SAM50 caused a marked decrease in the mitochondrial membrane potential in BCR-ABL-transduced HSPCs, in accordance with our previous findings (Fig. 2A, Capala et al, submitted). However, the level of ROS measured in BCR-ABL HSPCs was not significantly altered upon SAM50 downregulation (Fig. 2B). To investigate whether mitochondrial oxidative phosphorylation was affected by SAM50 depletion we used the XF^e Analyzer of extracellular flux to measure the oxygen consumption

Figure 2. Depletion of SAM50 causes mitochondrial dysfunction in BCR-ABL-expressing HSPCs. (A) 5×10^3 CB CD34[+] stem/progenitor cells co-transduced with BCR-ABL and either control scrambled shRNA vector (shSCR) or with SAM50-targeting shRNA vectors (shSAM50) were sorted and plated on MS5 stromal cells. Suspension cells were harvested after 14 days of co-culture and stained with DilC to measure changes in mitochondrial membrane potential. Representative FACS plots and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of 3 independent experiments is shown with standard deviation. (B) Suspension cells from the double-transduced co-cultures (BCR-ABL and shSCR or shSAM50) were harvested after 14 days and stained with CellROX to measure oxidative stress. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of 3 independent experiments is shown with standard deviation. (C) K562 cells were transduced with either shSCR or shSAM50 and analyzed by the XF^e Analyzer of extracellular flux. OCR and ECAR are represented as changes relative to control. Average of 3 independent experiments is shown with standard deviation. (D) Suspension cells from the double-transduced co-cultures (BCR-ABL and shSCR or shSAM50) as described in panel A were harvested after 14 days and analyzed by the XFe Analyzer of extracellular flux. OCR is represented as change relative to control. Average of 3 independent experiments is shown with standard deviation. OCR − oxygen consumption rate; ECAR - extracellular acidification rate. * $P<0.05$, *** $P<0.001$.

rate (OCR) and extracellular acidification rate (ECAR) of the BCR-ABL-expressing leukemic K562 cell line. OCR levels of shSAM50-transduced K562 cells were strongly reduced compared to control shSCR-transduced cells, indicative of de-

creased mitochondrial respiration. At the same time, ECAR levels were not significantly changed, indicating that glycolysis was not affected by SAM50 downregulation (Fig. 2C). Subsequently, we measured OCR in BCR-ABL and shSAM50 dou-

ble-transduced CD34$^+$ CB cells. Also in this case, the OCR levels were significantly downregulated upon SAM50 depletion (Fig. 2D). Overall, these results showed that SAM50 downregulation negatively affected mitochondrial membrane potential and resulted in decreased mitochondrial respiration in BCR-ABL-expressing cells.

DOWNREGULATION OF SAM50 IN NORMAL HSPCs DOES NOT AFFECT PROLIFERATION, PROGENITOR AND STEM CELL FREQUENCIES OR MITOCHONDRIAL MEMBRANE POTENTIAL, BUT DECREASES REPLATING CAPACITY

Leukemic cells have been proven to be more sensitive to therapeutics targeting mitochondrial metabolism than normal hematopoietic cells [22]. Therefore, we investigated whether downregulation of SAM50 could also be used as a strategy to specifically target leukemic, but not normal hematopoietic cells. In order to study the long-term effects of SAM50 downregulation in human HSPCs, shRNA-transduced CD34$^+$ CB cells were sorted and plated on a bone marrow stromal feeder layer for 5 weeks. The efficiency of SAM50 downregulation in shRNA-transduced cells was assessed by Western blot (Fig. 3A). During the co-culture, SAM50-depleted cells showed no proliferative disadvantage compared to control shSCR-transduced cells (Fig. 3B). Differentiation along the myeloid lineage was also unaffected (Fig. 3C). In addition, SAM50 downregulation did not result in a significant decrease of progenitor frequency, as assessed by CFC assay, or in the most primitive stem

cell frequency in LTC-IC assay compared to control (1:302 vs. 1:224, p=0.4). Also, the mitochondrial functions as assessed by the measurement of the mitochondrial membrane potential and ROS levels were not different between SAM50-depleted and control HSPCs (Fig. 3F, G). However, the replating capacity of colony forming cells was strongly reduced upon SAM50 downregulation. This suggested that while under steady state conditions normal HSPCs were not affected by depletion of SAM50, normal HSPCs did heavily rely on SAM50 expression during stress conditions imposed on cells by serial replating of CFCs.

BCR–ABL–TRANSDUCED HUMAN HSPCs SHOW INCREASED MITOCHONDRIAL ACTIVITY

We speculated that the high sensitivity of BCR-ABL-expressing cells to SAM50 downregulation could originate from their increased mitochondrial activity. To this end, we directly compared mitochondrial membrane potential and ROS levels in normal and BCR-ABL-expressing human HSPCs. CD34$^+$ cells isolated from a single batch of cord blood were used to eliminate inter-batch variability, and either co-transduced with BCR-ABL and shRNA constructs, or transduced with shRNA only. Sorted cells were plated in stromal co-cultures and FACS analyses were performed at the same time for normal and BCR-ABL-transduced cells. FACS analysis of DilC dye showed that the mitochondrial membrane potential was markedly increased in BCR-ABL-expressing HSPCs, compared to controls (Fig. 4A). ROS levels in BCR-ABL HSPCs were also increased, albeit to levels that were not statistically significant (Fig. 4B). Overall, these data

indicate that the mitochondrial activity of leukemic cells is altered, suggesting that this might explain their specific sensitivity to the disruption of mitochondrial function.

CYTOKINE-DRIVEN PROLIFERATION OF NORMAL HSPCs RESULTS IN INCREASED MITOCHONDRIAL ACTIVITY AND INCREASED SENSITIVITY TO SAM50 DOWNREGULATION

The BCR-ABL oncogene is a potent driver of proliferation of transformed CB cells [34,37]. Therefore, we wondered whether inducing a high proliferation rate on CB CD34[+] cells by culturing them in a cytokine-rich medium would increased their mitochondrial activity and render them more sensitive to SAM50 depletion. CD34[+] CB cells were cultured in a co-culture setting with or without the addition of cytokines (20 ng/mL stem cell factor and interleukin-3). As expected, cells cultured with cytokines showed a strongly increased proliferation (compare shSCR control data in Fig. 3B without cytokines with data in Fig. 5C with cytokines). FACS analysis using DilC staining showed a significant increase in mitochondrial membrane potential in cells cultured with the addition of cytokines (Fig. 5A). Also the ROS levels produced within these cells were increased, although the results did not reach statistical significance (Fig. 5B). Together, this showed that the cytokine-induced proliferation is paralleled by increased mitochondrial activity in CB cells. Next, we transduced CD34[+] CB cells with the SAM50-targeting or shSCR control shRNA construct, and transduced cells were sorted and plated on stroma in the same cytokine-rich medium. Strikingly, under the proliferation-driving culture conditions, shSAM50-transduced CB cells showed a marked proliferative disadvantage, which was not seen in the regular CB co-cultures without the extra addition of cytokines (Fig. 5B and 3B). Also the mitochondrial membrane potential was significantly decreased and ROS levels were slightly, but not significantly, reduced (Fig. 5D). Overall, these data suggested that high proliferation rate induced by cytokines increased the mitochondrial activity in CB cells, which in turn made them more sensitive to the disruption of mitochondrial functions by SAM50 downregulation.

DISCUSSION

Interfering with mitochondrial metabolism has previously been shown to be an effective strategy to specifically target leukemic cells. In AML cells, inhibition of mitochondrial translation with the drug tigecycline or by shRNA-mediated knockdown of the EF-Tu mitochondrial translation factor showed a selective anti-leukemic effect [22]. In chronic lymphocytic leukemia (CLL), interrupting the mitochondrial respiratory chain by a benzodiazepine derivative PK11195 specifically induced cell death in leukemic but not normal T and B-cells [38]. Also, in BCR-ABL-expressing leukemic cells pharmacological inhibition or decreased expression of small GTPase RAC2 selectively targeted leukemic and not normal HSPCs by decreasing their mitochondrial activity and ROS production [29,39,40] (Capala et al. submitted). In the current study we show that shRNA-mediated downregulation of a mitochondrial protein SAM50 resulted in a strongly reduced proliferation of leukemic but not

normal human HSPCs. The replating capacity of leukemic cells both in co-culture and CFC assay was strongly decreased, suggesting that also the more primitive, LSC-containing population was affected. Also the mitochondrial functions were affected by SAM50 downregulation in BCR-ABL expressing, but not normal CB cells.

SAM50, as a part of the MIB complex, is necessary for the assembly of the mitochondrial respiratory chain and formation of cristae [33]. In agreement with this, our experiments showed that downregulation of SAM50 resulted not only in a decreased mitochondrial membrane potential in BCR-ABL-expressing human HSPCs but also lower OCR, indicative of decreased oxidative phosphorylation. SAM50 expression was not increased in AML CD34+ cells as compared to normal bone marrow (NBM) CD34+ cells (unpublished observation) and therefore could not account for the dependence of leukemic cells on SAM50. When we directly compared normal and BCR-ABL-transduced CB CD34+ cells, we observed an increased mitochondrial

Figure 3. **SAM50 downregulation affects replating capacity, but not proliferation or pro-genitor and stem cell frequencies of human HSPCs in stromal co-cultures.** (A) Cord blood (CB) CD34[+] stem/progenitor cells were transduced with control scrambled shRNA vector (shSCR) or with SAM50-targeting shRNA vectors (shSAM50), sorted and used for RNA extraction. Transduced cells were sorted and used for Western blot analysis to determine SAM50 protein levels. Quantification of protein expression relative to control is indicated above each lane. (B) 5×10^4 transduced and sorted cells per group were plated on MS5 stromal cells and kept in the co-culture for 5 weeks; cultures were demi-depopulated weekly for analysis. Weekly cumulative cell growth is shown for a representative experiment of 4 independent experiments. (C) Suspension cells from MS5 co-cultures as described in panel B were analyzed for the expression of myeloid surface markers at week 2 of co-cullture. Distribution of differentiation (D) Suspension cells from MS5 co-cultures as described in panel B were analyzed for progenitor frequency by CFC assay. 10^4 cells from each co-culture were plated in a CFC assay in methylcellulose in duplicate, and colonies were evaluated 2 weeks after plating. CFC cells were then harvested and 10^5 cells were re-plated to form secondary CFCs. CFU-GM and BFU-E numbers are shown from a representative of 3 independent experiments; error bars indicate standard deviation. (E) LTC-IC frequencies were determined in limiting dilution on MS5 stromal cells. After 5 weeks of culture methylcellulose was added and colonies were scored two weeks later. Poisson statistics were used to calculate LTC-IC frequencies. (F) Suspension cells from the co-cultures as described in panel B were harvested after 14 days and stained with DilC to measure changes in mitochondrial membrane potential. Representative FACS plots and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of 3 independent experiments is shown with standard deviation. (G) Suspension cells from the co-cultures as described in panel B were harvested after 14 days and stained with CellROX to measure oxidative stress. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of 3 independent experiments is shown with standard deviation. CFU -GM, colony-forming unit-granulocyte-macrophage; BFU-E, burst forming unit-erythroid. * $P<0.05$, *** $P<0.001$.


Figure 4. **Increased mitochondrial activity of BCR-ABL-transduced human HSPCs.** (A) 5×10^4 CB CD34[+] stem/progenitor cells transduced either control scrambled shRNA vector (shSCR) or with SAM50-targeting shRNA vectors (shSAM50) as well as 5×10^3 BCR-ABL and shRNA double-transduced cells were sorted and plated on MS5 stromal cells. Suspension cells were harvested after 14 days of co-culture and stained with DilC to measure changes in mitochondrial membrane potential. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of 3 independent experiments is shown with standard deviation. (B) Suspension cells from the co-cultures as described in panel A were harvested after 14 days and stained with CellROX to measure oxidative stress. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of 3 independent experiments is shown with standard deviation. *** $P<0.001$.

Figure 5. Increased mitochondrial activity and increased sensitivity to SAM50 downregulation in normal HSPCs upon cytokine stimulation. (A) $5×10^4$ CB CD34[+] stem/progenitor cells were plated on MS5 stromal cells in Gartner's medium with or without the addition of cytokines (20 ng/mL SCF and IL-3). Suspension cells were harvested after 14 days of co-culture and stained with DilC to measure changes in mitochondrial membrane potential. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of 3 independent experiments is shown with standard deviation. (B) Suspension cells from the co-cultures as described in panel A were harvested after 14 days and stained with CellROX to measure oxidative stress. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of 3 independent experiments is shown with standard deviation. *** $P<0.001$. (C) CB CD34[+] cells were transduced with control shSCR or with shSAM50 vectors, and $5×10^4$ transduced and sorted cells per group were plated on

membrane potential and (although not statistically significant) increased ROS levels. This was in accordance with previous findings, where increased mitochondrial biogenesis and increased respiratory rates were shown to be characteristic for leukemic cells [22,38]. Thus, we concluded that an increase in mitochondrial activity of leukemic cells makes them more vulnerable to strategies disrupting mitochondrial functions

Although in the steady state the proliferation and progenitor frequency of normal CB cells in co-culture was not affected by SAM50 downregulation, the replating capacity of progenitor cells was strongly reduced. This suggests that upon stress, possibly due to increased energy requirements, cells rely more strongly upon intact mitochondrial functions. Malignant transformation, with its increased proliferation and metabolic rate, also creates stress within the cells. Moreover, accumulation of ROS results in so-called cancer-associated oxidative stress [15]. Although elevated ROS levels can be advantageous for malignant cells by inducing pro-survival signaling pathways, too high ROS cause detrimental DNA and protein damage [41]. Therefore, disruption of the redox balance in either direction can negatively affect growth and survival of transformed cells.

Addition of cytokines to the co-culture medium not only increased the proliferation rate of normal CB cells, but also rendered them more sensitive to SAM50 downregulation. This effect could simply be a result of a higher proliferation rate that requires more energy produced by the mitochondria, but also a direct effect of cytokine signaling. Several growth factors and cytokines, including IL-3, were found to stimulate ROS production [42,43]. In accordance with that, in our study we found not only increased mitochondrial membrane potential, but also increased, albeit not statistically significant, ROS levels in cytokine-stimulated CB cells. Although the effect of SAM50 downregulation on the growth of CB cells in cytokine-rich cultures was clear, it was less dramatic than in BCR-ABL-transduced CB cells. This suggests that driving cell proliferation is not the only aspect of the oncogenic kinase activity that is responsible for the increased sensitivity to SAM50 downregulation. Elucidating these additional mechanisms that make leukemic cells highly dependent on mitochondrial functions could contribute to more efficient and selective targeting of leukemia.

MS5 stromal cells and kept in the co-culture for 5 weeks, in medium supplemented with cytokines. Co-cultures were demi-depopulated weekly for analysis. Weekly cumulative cell growth is shown for a representative experiment of 3 independent experiments. (D) Suspension cells from co-cultures like described in panel C were harvested after 14 days of co-culture and stained with DilC to measure changes in mitochondrial membrane potential. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of 3 independent experiments is shown with standard deviation. (D) Suspension cells from the co-cultures as described in panel C were harvested after 14 days and stained with CellROX to measure oxidative stress. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of 3 independent experiments is shown with standard deviation. * $P<0.05$, ** $P<0.01$

ACKNOWLEDGMENTS

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicate no potential conflicts of interest.

REFERENCE LIST

1. Racker E (1972) Bioenergetics and the Problem of Tumor Growth: An understanding of the mechanism of the generation and control of biological energy may shed light on the problem of tumor growth. American Scientist 60: 56-63.

2. Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. The Journal of General Physiology 8: 519-530.

3. Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11: 325-337.

4. Boveris A, Chance B (1973) The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J 134: 707-716.

5. Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, Baracca A, Tallini G, Martinuzzi A, Lenaz G, Rugolo M, Romeo G (2006) Defective Oxidative Phosphorylation in Thyroid Oncocytic Carcinoma Is Associated with Pathogenic Mitochondrial DNA Mutations Affecting Complexes I and III. Cancer Research 66: 6087-6096.

6. Carew JS, Nawrocki ST, Xu RH, Dunner K, Jr., McConkey DJ, Wierda WG, Keating MJ, Huang P (2004) Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia 18: 1934-1940.

7. Turrens JF (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552: 335-344.

8. Meyer M, Pahl HL, Baeuerle PA (1994) Regulation of the transcription factors NF-kB and AP-1 by redox changes. Chemico-Biological Interactions 91: 91-100.

9. Sun Y, Oberley LW (1996) Redox regulation of transcriptional activators. Free Radical Biology and Medicine 21: 335-348.

10. Ding M, Li JJ, Leonard SS, Ye JP, Shi X, Colburn NH, Castranova V, Vallyathan V (1999) Vanadate-induced activation of activator protein-1: role of reactive oxygen species. Carcinogenesis 20: 663-668.

11. Wang S, Leonard SS, Ye J, Ding M, Shi X (2000) The role of hydroxyl radical as a messenger in Cr(VI)-induced p53 activation. American Journal of Physiology - Cell Physiology 279: C868-C875.

12. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, Lee LA, Semenza GL, Dang CV (2007) HIF-dependent Antitumorigenic Effect of Antioxidants In Vivo. Cancer Cell 12: 230-238.

13. Abdel-Wahab O, Adli M, Lafave LM, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, Perna F, Zhao X, Taylor JE, Park CY, Carroll M, Melnick A, Nimer SD, Jaffe JD, Aifantis I, Bernstein BE, Levine RL (2012) ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression. Cancer Cell 22: 180-193.

14. Bell EL, Emerling BM, Chandel NS (2005) Mitochondrial regulation of oxygen sensing. Mitochondrion 5: 322-332.

15. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591.

16. Kumar B, Kumar A, Pandey BN, Mishra KP, Hazra B (2009) Role of mitochondrial oxidative stress in the apoptosis induced by diospyrin diethylether in human breast carcinoma (MCF-7) cells. Mol Cell Biochem 320: 185-195.

17. Hanahan D, Weinberg R (2011) Hallmarks of Cancer: The Next Generation. Cell 144: 646-674.

18. Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, Rhee SG (1997) Epidermal Growth Factor (EGF)--induced Generation of Hydrogen Peroxide: Role In Egf Receptor-Mediated Tyrosine Phosphorylation. Journal of Biological Chemistry 272: 217-221.

19. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T (1995) Requirement for Generation of H_2O_2 for Platelet-Derived Growth Factor Signal Transduction. Science 270: 296-299.

20. Vaughn AE, Deshmukh M (2008) Glucose Metabolism Inhibits Apoptosis in Neurons and Cancer Cells by Redox Inactivation of Cytochrome c. Nat Cell Biol 10: 1477-1483.

21. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, Brugge JS (2009) Antioxidant and Oncogene Rescue of Metabolic Defects Caused by Loss of Matrix Attachment. Nature 461: 109-113.

22. Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z, Hurren R, Jitkova Y, Gronda M, Maclean N, Lai CK, Eberhard Y, Bartoszko J, Spagnuolo P, Rutledge AC, Datti A, Ketela T, Moffat J, Robinson BH, Cameron JH, Wrana J, Eaves CJ, Minden

MD, Wang JC, Dick JE, Humphries K, Nislow C, Giaever G, Schimmer AD (2011) Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20: 674-688.

23. Flis K, Irvine D, Copland M, Bhatia R, Skorski T (2012) Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. Leuk Lymphoma 53: 2474-2478.

24. Sallmyr A, Fan J, Datta K, Kim KT, Grosu D, Shapiro P, Small D, Rassool F (2008) Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood 111: 3173-3182.

25. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, Greenfield EA, Salgia R, Griffin JD (2000) The BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic Cells. Journal of Biological Chemistry 275: 24273-24278.

26. Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T (2008) BCR//ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia 22: 1969-1972.

27. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, Nieborowska-Skorska M, Blasiak J, Skorski T (2004) BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen speciesGÇôdependent DNA double-strand breaks. Blood 104: 3746-3753.

28. Naughton R, Quiney C, Turner SD, Cotter TG (2009) Bcr-Abl-mediated redox reg-

ulation of the PI3K/AKT pathway. Leukemia 23: 1432-1440.

29. Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wiktor-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA, Skorski T (2012) Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 119: 4253-4263.

30. Humphries AD, Streimann IC, Stojanovski D, Johnston AJ, Yano M, Hoogenraad NJ, Ryan MT (2005) Dissection of the Mitochondrial Import and Assembly Pathway for Human Tom40. Journal of Biological Chemistry 280: 11535-11543.

31. Kozjak-Pavlovic V, Ross K, Benlasfer N, Kimmig S, Karlas A, Rudel T (2007) Conserved roles of Sam50 and metaxins in VDAC biogenesis. EMBO Rep 8: 576-582.

32. Kozjak V, Wiedemann N, Milenkovic D, Lohaus C, Meyer HE, Guiard B, Meisinger C, Pfanner N (2003) An Essential Role of Sam50 in the Protein Sorting and Assembly Machinery of the Mitochondrial Outer Membrane. Journal of Biological Chemistry 278: 48520-48523.

33. Ott C, Ross K, Straub S, Thiede B, Goetz M, Goosmann C, Krischke M, Mueller MJ, Krohne G, Rudel T, Kozjak-Pavlovic V (2012) Sam50 Functions in Mitochondrial Intermembrane Space Bridging and Biogenesis of Respiratory Complexes. Molecular and Cellular Biology 32: 1173-1188.

34. Rizo A, Horton SJ, Olthof S, Dontje B, Ausema A, van Os R, van den Boom V, Vellenga E, de Haan G, Schuringa JJ (2010) BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34[+] cells. Blood 116: 4621-4630.

35. Schuringa JJ, Chung KY, Morrone G, Moore MA (2004) Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J Exp Med 200: 623-635.

36. Zamora M, Merono C, Vinas O, Mampel T (2004) Recruitment of NF-kB into Mitochondria Is Involved in Adenine Nucleotide Translocase 1 (ANT1)-induced Apoptosis. Journal of Biological Chemistry 279: 38415-38423.

37. Chalandon Y, Jiang X, Hazlewood G, Loutet S, Conneally E, Eaves A, Eaves C (2002) Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming. Blood 99: 3197-3204.

38. Jitschin R, Hofmann AD, Bruns H, Giessl A, Bricks J, Berger J, Saul D, Eckart MJ, Mackensen A, Mougiakakos D (2014) Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood 123: 2663-2672.

39. Capala ME, Vellenga E, Schuringa JJ (2014) ELMO1 Is Upregulated in AML CD34[+] Stem/Progenitor Cells, Mediates Chemotaxis and Predicts Poor Prognosis in Normal Karyotype AML. PLoS One 9: e111568.

40. Sengupta A, Arnett J, Dunn S, Williams DA, Cancelas JA (2010) Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood 116: 81-84.

41. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95.

42. Maraldi T, Prata C, Vieceli Dalla Sega F, Caliceti C, Zambonin L, Fiorentini D, Hakim G (2009) NAD(P)H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells. Free Radic Res 43: 1111-1121.

43. Zhou F, Shen Q, Claret FX (2013) Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. J Leukoc Biol 94: 423-429.